The candidate vaccine raised neutralising antibodies in all dose cohorts after one immunisation , with seroconversion rates of @ % ( n = @ ) in the low-dose group , @ % ( n = @ ) in the medium-dose group , and @ % ( n = @ ) in the high-dose group .